OpGen, Inc. (OPGN)
USD 1.07
(-3.6%)
USD 1.07
(-3.6%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.68 Million USD | 11.05% |
| 2022 | -34.56 Million USD | -49.62% |
| 2021 | -23.1 Million USD | -7.48% |
| 2020 | -21.49 Million USD | -95.91% |
| 2019 | -10.97 Million USD | 16.76% |
| 2018 | -13.18 Million USD | 13.51% |
| 2017 | -15.23 Million USD | 19.83% |
| 2016 | -19 Million USD | -26.23% |
| 2015 | -15.05 Million USD | -170.62% |
| 2014 | -5.56 Million USD | 46.13% |
| 2013 | -10.33 Million USD | -15.57% |
| 2012 | -8.93 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.7 Million USD | 89.96% |
| 2024 Q2 | -1.54 Million USD | 9.15% |
| 2023 FY | -30.74 Million USD | 11.05% |
| 2023 Q4 | -16.95 Million USD | -375.56% |
| 2023 Q1 | -5.07 Million USD | -11.12% |
| 2023 Q2 | -5.15 Million USD | -1.7% |
| 2023 Q3 | -3.56 Million USD | 30.85% |
| 2022 Q1 | -5.84 Million USD | 1.24% |
| 2022 Q4 | -4.56 Million USD | 66.24% |
| 2022 FY | -34.56 Million USD | -49.62% |
| 2022 Q3 | -13.51 Million USD | -156.31% |
| 2022 Q2 | -5.27 Million USD | 9.81% |
| 2021 Q4 | -5.91 Million USD | -16.37% |
| 2021 Q1 | -6.26 Million USD | -3.83% |
| 2021 FY | -23.1 Million USD | -7.48% |
| 2021 Q2 | -6.13 Million USD | 1.96% |
| 2021 Q3 | -5.08 Million USD | 17.14% |
| 2020 FY | -21.49 Million USD | -95.91% |
| 2020 Q4 | -6.03 Million USD | 2.36% |
| 2020 Q2 | -6.51 Million USD | -63.17% |
| 2020 Q3 | -6.17 Million USD | 5.24% |
| 2020 Q1 | -3.99 Million USD | -59.59% |
| 2019 FY | -10.97 Million USD | 16.76% |
| 2019 Q1 | -3.76 Million USD | -2.28% |
| 2019 Q4 | -2.5 Million USD | 26.93% |
| 2019 Q3 | -3.42 Million USD | -32.72% |
| 2019 Q2 | -2.58 Million USD | 31.39% |
| 2018 Q4 | -3.67 Million USD | -13.87% |
| 2018 Q3 | -3.23 Million USD | 0.79% |
| 2018 Q1 | -3.01 Million USD | -3.92% |
| 2018 FY | -13.18 Million USD | 13.51% |
| 2018 Q2 | -3.25 Million USD | -7.96% |
| 2017 FY | -15.23 Million USD | 19.83% |
| 2017 Q4 | -2.9 Million USD | 9.21% |
| 2017 Q3 | -3.19 Million USD | 23.71% |
| 2017 Q2 | -4.18 Million USD | 15.37% |
| 2017 Q1 | -4.95 Million USD | -5.04% |
| 2016 Q1 | -4.47 Million USD | 7.16% |
| 2016 FY | -19 Million USD | -26.23% |
| 2016 Q4 | -4.71 Million USD | 1.92% |
| 2016 Q3 | -4.8 Million USD | 4.17% |
| 2016 Q2 | -5.01 Million USD | -12.03% |
| 2015 Q2 | -3.05 Million USD | -20.66% |
| 2015 Q1 | -2.53 Million USD | -88.61% |
| 2015 Q3 | -4.65 Million USD | -52.41% |
| 2015 Q4 | -4.82 Million USD | -3.59% |
| 2015 FY | -15.05 Million USD | -170.62% |
| 2014 Q1 | -1.19 Million USD | 60.48% |
| 2014 Q4 | -1.34 Million USD | 15.13% |
| 2014 Q3 | -1.58 Million USD | -9.03% |
| 2014 FY | -5.56 Million USD | 46.13% |
| 2014 Q2 | -1.44 Million USD | -21.64% |
| 2013 Q4 | -3.01 Million USD | 0.0% |
| 2013 FY | -10.33 Million USD | -15.57% |
| 2012 FY | -8.93 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -215.24 Million USD | 92.711% |
| Prenetics Global Limited | -52.51 Million USD | 70.125% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -260.987% |
| CareDx, Inc | -101.9 Million USD | 84.604% |
| Exact Sciences Corporation | -215.01 Million USD | 92.703% |
| Exagen Inc. | -22.83 Million USD | 31.302% |
| Inotiv, Inc. | -81.46 Million USD | 80.741% |
| Guardant Health, Inc. | -564.72 Million USD | 97.222% |
| Biodesix, Inc. | -41.34 Million USD | 62.052% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -504.895% |
| Precipio, Inc. | -7.62 Million USD | -105.886% |
| iSpecimen Inc. | -11.16 Million USD | -40.46% |
| Natera, Inc. | -446.24 Million USD | 96.484% |
| Aspira Women's Health Inc. | -18.85 Million USD | 16.781% |
| Standard BioTools Inc. | -76.6 Million USD | 79.519% |
| 23andMe Holding Co. | -321.35 Million USD | 95.118% |
| Castle Biosciences, Inc. | -67.97 Million USD | 76.921% |
| Personalis, Inc. | -109.93 Million USD | 85.729% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 83.886% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -43.231% |
| T2 Biosystems, Inc. | -49.66 Million USD | 68.411% |
| Myriad Genetics, Inc. | -123.7 Million USD | 87.317% |
| ICON Public Limited Company | 956.15 Million USD | 101.641% |
| NeoGenomics, Inc. | -107.73 Million USD | 85.438% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -260.987% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 101.43% |
| RadNet, Inc. | 98.69 Million USD | 115.896% |
| MDxHealth SA | -27.32 Million USD | 42.59% |
| Psychemedics Corporation | -2.92 Million USD | -437.093% |
| Illumina, Inc. | -1.06 Billion USD | 98.532% |
| Check-Cap Ltd. | -19.28 Million USD | 18.658% |
| Twist Bioscience Corporation | -220.83 Million USD | 92.896% |
| DarioHealth Corp. | -56.18 Million USD | 72.079% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 78.419% |
| Sera Prognostics, Inc. | -39.82 Million USD | 60.603% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -49.12% |
| OPKO Health, Inc. | -157.02 Million USD | 90.009% |
| Medpace Holdings, Inc. | 336.82 Million USD | 104.658% |
| Neogen Corporation | 58.66 Million USD | 126.743% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -52.565% |
| Prenetics Global Limited | -52.51 Million USD | 70.125% |
| Mainz Biomed B.V. | -26.64 Million USD | 41.12% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -96.764% |
| Trinity Biotech plc | -27.04 Million USD | 41.991% |
| Neuronetics, Inc. | -30.55 Million USD | 48.653% |
| Sotera Health Company | 276.69 Million USD | 105.67% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -96.764% |